NASDAQ: LBRXLb Pharmaceuticals Inc Stock
$42.57-0.47 (-1.09%)
Updated Sep 16, 2026
LBRX Price
$42.57
Fair Value Price
$9.75
Market Cap
$1.37B
52 Week Low
$13.36
52 Week High
$50.16
P/E
304.07x
P/B
4.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$85.69M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$82M
Beta
0.6
Next Earnings
Nov 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LBRX Overview
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LBRX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LBRX
Ranked#403 of 461
Ranked#403 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.39 | A | |
| $42.21 | A | |
| $111.81 | A |
Be the first to know about important LBRX news, forecast changes, insider trades & much more!
LBRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LBRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LBRX ($42.57) is overvalued by 336.73% relative to our estimate of its Fair Value price of $9.75 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LBRX ($42.57) is not significantly undervalued (336.73%) relative to our estimate of its Fair Value price of $9.75 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LBRX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more LBRX due diligence checks available for Premium users.
Valuation
LBRX fair value
Fair Value of LBRX stock based on Discounted Cash Flow (DCF)
Price
$42.57
Fair Value
$9.75
Overvalued by
336.73%
LBRX ($42.57) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LBRX ($42.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LBRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
304.07x
Industry
9.99x
Market
44.18x
LBRX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
LBRX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
LBRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.13x
Industry
5.23x
LBRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LBRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$51.6M
Profit Margin
0%
LBRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$361.7M
Liabilities
$29.3M
Debt to equity
0.09
LBRX's short-term assets ($355.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LBRX's short-term assets ($355.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LBRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$37.6M
Investing
$89.0k
Financing
-$19.0k
LBRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LBRX vs Biotech Stocks
Lb Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.